Researchers Identify Five Distinct Subtypes of Common Fatty Liver Disease With Different Risk Profiles
Researchers from Mayo Clinic and Virginia Tech analyzed data from over 4,600 patients to identify five biologically distinct subtypes of metabolic dysfunction-associated steatotic liver disease, each following different disease progression pathways and presenting different health risks. The analysis revealed that inherited genetic factors define some forms of the disease, which carry elevated risks for advanced liver complications regardless of metabolic risk factors. This stratification could enable personalized treatment approaches tailored to the specific biological mechanisms driving disease in individual patients.
Researchers combined whole exome sequencing data with comprehensive clinical records from thousands of patients to map disease patterns that would be invisible when treating MASLD as a single condition. The analysis incorporated information about liver function tests, weight metrics, cholesterol profiles, and associated health conditions like diabetes and sleep disorders. This large-scale computational approach revealed that some disease variants arise primarily from inherited genetic variations rather than obesity or metabolic dysfunction, suggesting fundamentally different biological mechanisms at work.
The study leveraged Mayo Clinic's Research Data Atlas and the Tapestry Study, which has assembled genetic information from over 100,000 participants paired with their medical histories. This infrastructure enabled researchers to systematically examine how inherited genetic differences correlate with disease emergence and progression patterns across large populations, providing the scale necessary to identify statistically meaningful patient subgroups.
This stratification could reshape how nearly 2 billion affected adults worldwide receive treatment, potentially improving outcomes by targeting interventions to specific disease biology rather than applying uniform approaches. Patients with genetically-driven subtypes may particularly benefit, as they currently face advanced liver complications despite lacking traditional metabolic risk factors—meaning current prevention strategies may miss them entirely. However, translating these five subtypes into clinical practice would require development of accessible diagnostic tests and corresponding treatment protocols, representing substantial implementation challenges before widespread clinical adoption becomes feasible.